Senseonics Holdings (SENS) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this medical technology company would post a loss of $0.03 per share when it actually produced a loss of $0.02, delivering a surprise of 33.33%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Senseonics, which b ...

Company Performance - 10x Genomics reported a quarterly loss of $0.36 per share, better than the Zacks Consensus Estimate of a loss of $0.45, and an improvement from a loss of $0.50 per share a year ago, representing an earnings surprise of 20% [1] - The company posted revenues of $154.88 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 16.24%, and up from $141.01 million in the same quarter last year [2] - Over the last four quarters, 10x Genomics has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - 10x Genomics shares have declined approximately 42.1% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.37 on revenues of $146.51 million, and for the current fiscal year, it is -$1.47 on revenues of $609.56 million [7] Industry Outlook - The Medical Info Systems industry, to which 10x Genomics belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of 10x Genomics may be influenced by the overall industry outlook, as empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]

Toast (TOST) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Michael Senno - Senior VP of Finance & Strategy, Treasury and Investor RelationsAman Narang - Co-Founder, CEO & DirectorElena Gomez - President & CFOTimothy Chiodo - Managing DirectorDarrin Peller - Managing DirectorDominic Ball - VP - Equity ResearchRayna Kumar - Managing Director - Fintech Equity ResearchAndrew Bauch - Director - Equity ResearchJeremy Sahler - Software Equity Research Conference Call Participants Stephen Shel ...

Toast (TOST) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Good afternoon. My name is Tamika, and I will be your conference operator today. At this time, I would like to welcome everyone to the Toast First Quarter twenty twenty five Earnings Conference Call. Today's call will be forty five minutes. I will now turn the call over to Michael Sinnell, Senior Vice President of Finance. You may begin your conference. Speaker1 Thank you, Tamika, and welcome everybody to Toast's earnings conference call f ...

Core Points - Autoliv, Inc. held its 2025 Annual General Meeting of Stockholders on May 8, 2025, where several key proposals were approved [1] - Jan Carlson continues to serve as the Chairman of the Board [2] - The company reported sales of $10.4 billion in 2024 and operates in 25 countries with 65,000 employees [4] Board and Committees - The following directors were elected for a one-year term ending at the 2026 AGM: Mikael Bratt, Laurie Brlas, Jan Carlson, Leif Johansson, Adriana Karaboutis, Franz-Josef Kortüm, Frédéric Lissalde, Xiaozhi Liu, Gustav Lundgren, Martin Lundstedt, and Thaddeus "Ted" Senko [5] - The Audit and Risk Committee is chaired by Ted Senko, with members Laurie Brlas, Adriana Karaboutis, and Gustav Lundgren [5] - The Leadership Development and Compensation Committee is chaired by Frédéric Lissalde, with members Leif Johansson, Xiaozhi Liu, and Martin Lundstedt [5] - The Nominating and Corporate Governance Committee is chaired by Leif Johansson, with members Laurie Brlas, Franz-Josef Kortüm, and Frédéric Lissalde [5] Company Overview - Autoliv is the worldwide leader in automotive safety systems, developing products such as airbags, seatbelts, and mobility safety solutions [3][4] - In 2024, Autoliv's products saved nearly 37,000 lives and reduced over 600,000 injuries [3]

Solventum (SOLV) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance CommunicationsBryan Hanson - CEOWayde McMillan - Chief Financial OfficerPatrick Wood - Managing DirectorDavid Roman - Managing DirectorTravis Steed - Managing Director - Equity Research Conference Call Participants Rick Wise - AnalystJason Bednar - Senior Research AnalystNone - AnalystSteven Valiquette - MD & Senior Equity Research Analyst - Coveri ...

Financial Data and Key Metrics Changes - The company reported first quarter sales of $2.1 billion, reflecting a 4.3% increase on an organic basis and a 2.6% increase on a reported basis [25] - Adjusted earnings per share (EPS) for the quarter was $1.34, exceeding expectations [31] - Gross margins were 55.6% of sales, slightly ahead of expectations but down 260 basis points compared to the prior year [29] Business Segment Data and Key Metrics Changes - The MedSurg segment generated $1.2 billion in sales, an increase of 6% on an organic basis, driven by strong performance in Infection Prevention and Surgical Solutions [27] - The Dental Solutions segment reported $328 million in revenue, a 0.4% increase on an organic basis, benefiting from new product launches despite market challenges [28] - The Health Information Systems (HIS) segment contributed $329 million in revenue, a 3.9% organic growth, supported by strong customer retention [28] - The Purification and Filtration segment delivered $242 million in sales, a 2.2% organic growth, led by bioprocessing filtration [28] Market Data and Key Metrics Changes - The company experienced a favorable foreign exchange impact, with currency now estimated to have a neutral effect on sales growth for the year, compared to a previous estimate of a 150 basis point headwind [34] - The overall market volumes remain challenged, particularly in the Dental segment, but the company is seeing resilience in its core restorative areas [28][84] Company Strategy and Development Direction - The company is committed to investing in key areas to support sustainable growth and margin improvement, focusing on five growth driver areas [12][21] - The ongoing separation process is on track, with over 30% of transition service agreements exited and significant progress in ERP deployments planned for the year [24] - The company anticipates completing the divestiture of the Purification and Filtration business by the end of 2025, which will allow for tuck-in M&A opportunities [19][21] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the headwinds from tariffs but expressed confidence in managing these challenges through mitigation strategies and strong business momentum [8][34] - The company raised its full-year organic sales growth guidance to a range of 1.5% to 2.5%, reflecting positive volume-driven performance across business segments [32] - Management emphasized the importance of delivering for customers and maintaining focus on long-term value creation despite short-term challenges [11][38] Other Important Information - The company has made cumulative repayments of $400 million on its $1.5 billion prepayable term loans, ending the quarter with $534 million in cash and equivalents [31] - Free cash flow for Q1 declined by $80 million, consistent with expectations due to planned payments and one-time separation costs [31] Q&A Session Summary Question: Confidence in underlying growth rate - Management expressed confidence in the 2.5% underlying growth rate, attributing it to strong commercial execution and analytics from distributor partners [40][42] Question: Quarterly cadence and impact of tariffs - Management clarified that tariffs primarily impact the bottom line, with expectations for most order timing impacts to be realized in Q3 [48][49] Question: Top line drivers in MedSurg - Management highlighted improvements in commercial execution and new product launches as key drivers for growth in the MedSurg segment [60][62] Question: Tariff impact and mitigation efforts - Management discussed ongoing mitigation strategies, including optimizing inventory and exploring selective pricing strategies to offset tariff impacts [68][72] Question: Performance in Dental segment relative to market - Management indicated that the Dental segment performed well relative to the market, supported by new product innovations [84]

Alarm.com (ALRM) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 and thank you for standing by. Welcome to Alarm.com's First Quarter 20 20 5 Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised today's conference is being recorded. I would now like to hand the conference over to your speaker today, Matthew Zartman, Vice President of Investor Relations. Please go ahead. Spea ...

Quarter Sales of $135.4 million, up 42% from a year earlier, Quarter Gross Margin of 29.7%, up 2.7% from a year earlier, Quarter Net Income of $19.1 million, up 168% from a year earlier, EPS $0.83 for the Quarter, Debt decreased $10.0 million. WOOD DALE, Ill, May 08, 2025 (GLOBE NEWSWIRE) -- Power Solutions International, Inc. (the "Company" or "PSI") (Nasdaq: PSIX), a leader in the design, engineering and manufacture of emission- certified engines and power systems, announced its financial results for the ...

Core Insights - Autoscope Technologies Corporation reported a quarterly cash dividend of $0.15 per share, payable on May 27, 2025 [1] - The company experienced a significant decrease in revenue and net income for the first quarter of 2025 compared to the same period in 2024 [4][9] Financial Performance - Revenue from operations was $2.2 million in Q1 2025, a 30% decrease from $3.1 million in Q1 2024 [4] - Royalty revenue decreased by 32% to $2.1 million in Q1 2025 from $3.1 million in Q1 2024 [8] - Product sales increased by 319% to $67,000 in Q1 2025 from $16,000 in Q1 2024, driven by sales of the Wrong Way product and Autoscope Analytics [4] - Gross margin improved to 98% in Q1 2025 from 96% in Q1 2024, with royalty gross margin at 100% compared to 97% in the prior year [5] - Operating expenses decreased by 9% to $1.7 million in Q1 2025 from $1.9 million in Q1 2024 [6] - Net income fell by 58% to $0.4 million in Q1 2025, or $0.07 per share, down from $0.9 million, or $0.16 per share, in Q1 2024 [9] Liquidity and Capital Resources - Cash and cash equivalents decreased to $0.6 million as of March 31, 2025, from $4.4 million on December 31, 2024, primarily due to a special dividend paid in February 2025 [10] - Net cash provided by operating activities was $1.0 million in Q1 2025, compared to a net cash used of $34,000 in Q1 2024 [11] - Net cash provided by investing activities was $1.9 million in Q1 2025, down from $3.1 million in Q1 2024 [12] - Net cash used by financing activities decreased to $6.6 million in Q1 2025 from $7.9 million in Q1 2024, attributed to a lower special dividend [13] Strategic Outlook - The company remains focused on operational efficiency and long-term value creation, with positive engagement from communities analyzing roadway behavior [14] - Economic uncertainties contributed to the anticipated decrease in royalty revenue, but the company believes these will have minimal impact for the remainder of the year [14]